Search Results

Business

Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office

Sosei Group Corporation, announces that at a meeting held on 15 February 2024, its Board of Directors resolved to change the corporate names of the Company and its subsidiaries and the location of the head office of the Company.

February 15, 2024

·

6 min read

Business

Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer

Sosei Group Corporation announces the appointment of Mr. Toshihiro Maeda as Chief Operating Officer.

January 5, 2024

·

4 min read

Business

Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia

Boehringer Ingelheim and Sosei Group Corporation announced they have entered a global collaboration and exclusive option-to-license agreement.

March 11, 2024

·

10 min read

Policy

Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea

Sosei Group Corporation announces that PIVLAZ™ 150 mg has received marketing approval from the Ministry of Food and Drug Safety in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing.

December 7, 2023

·

8 min read

Genetown

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

February 13, 2024

·

10 min read

Business

Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma

Sosei Group Corporation announces that the re-election of its Board of Directors and Executive Officers was approved at the Company’s 34th Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held in Tokyo.

March 27, 2024

·

4 min read

Genetown

Sosei Heptares Webinar Presentation for FY2023 Financial Results

Sosei Group Corporation will announce its earnings results and present operational highlights for the 12 months ended 31 December 2023 on Tuesday, 13 February 2024.

January 22, 2024

·

2 min read

Genetown

Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals

Sosei Group Corporation announces that Formosa Pharmaceuticals, Inc. has received approval from the US Food & Drug Administration for clobetasol propionate ophthalmic suspension 0.05%, for the treatment of post-operative inflammation and pain following ocular surgery.

March 6, 2024

·

3 min read

Genetown

Nxera Pharma is the New Name for Sosei Group

Nxera Pharma Co., Ltd. is pleased to announce the launch of its new company name, having received approval at the 34th Ordinary General Meeting of Shareholders held on 27 March 2024.

March 31, 2024

·

4 min read

Genetown

Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

Sosei Group Corporation announces it has regained full ownership from GSK of HTL0027477, a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in development as a potential new treatment for Inflammatory Bowel Diseases.

March 20, 2024

·

4 min read